Literature DB >> 12032707

Global gene and cell replacement strategies via stem cells.

K I Park1, J Ourednik, V Ourednik, R M Taylor, K S Aboody, K I Auguste, M B Lachyankar, D E Redmond, E Y Snyder.   

Abstract

The inherent biology of neural stem cells (NSCs) endows them with capabilities that not only circumvent many of the limitations of other gene transfer vehicles, but that enable a variety of novel therapeutic strategies heretofore regarded as beyond the purview of neural transplantation. Most neurodegenerative diseases are characterized not by discrete, focal abnormalities but rather by extensive, multifocal, or even global neuropathology. Such widely disseminated lesions have not conventionally been regarded as amenable to neural transplantation. However, the ability of NSCs to engraft diffusely and become integral members of structures throughout the host CNS, while also expressing therapeutic molecules, may permit these cells to address that challenge. Intriguingly, while NSCs can be readily engineered to express specified foreign genes, other intrinsic factors appear to emanate spontaneously from NSCs and, in the context of reciprocal donor-host signaling, seem to be capable of neuroprotective and/or neuroregenerative functions. Stem cells additionally have the appealing ability to 'home in' on pathology, even over great distances. Such observations help to advance the idea that NSCs - as a prototype for stem cells from other solid organs - might aid in reconstructing the molecular and cellular milieu of maldeveloped or damaged organs.

Entities:  

Mesh:

Year:  2002        PMID: 12032707     DOI: 10.1038/sj.gt.3301721

Source DB:  PubMed          Journal:  Gene Ther        ISSN: 0969-7128            Impact factor:   5.250


  31 in total

1.  Gene therapy for cancer: current status and prospects.

Authors:  Gregory P Kouraklis
Journal:  Dig Dis Sci       Date:  2003-05       Impact factor: 3.199

Review 2.  Drug discovery research targeting the CXC chemokine receptor 4 (CXCR4).

Authors:  Won-Tak Choi; Srinivas Duggineni; Yan Xu; Ziwei Huang; Jing An
Journal:  J Med Chem       Date:  2011-12-02       Impact factor: 7.446

Review 3.  Cell therapy in demyelinating diseases.

Authors:  Claire Rice; Christopher Halfpenny; Neil Scolding
Journal:  NeuroRx       Date:  2004-10

Review 4.  Strategies for achieving and monitoring myelin repair.

Authors:  Claire Rice; Neil Scolding
Journal:  J Neurol       Date:  2007-03-07       Impact factor: 4.849

Review 5.  Neurotrophin Signaling and Stem Cells-Implications for Neurodegenerative Diseases and Stem Cell Therapy.

Authors:  Subrata Pramanik; Yanuar Alan Sulistio; Klaus Heese
Journal:  Mol Neurobiol       Date:  2016-11-05       Impact factor: 5.590

6.  HIV Non-Nucleoside Reverse Transcriptase Inhibitor Efavirenz Reduces Neural Stem Cell Proliferation in Vitro and in Vivo.

Authors:  Jingji Jin; Bethany Grimmig; James Izzo; Lecia A M Brown; Charles Hudson; Adam J Smith; Jun Tan; Paula C Bickford; Brian Giunta
Journal:  Cell Transplant       Date:  2016-11       Impact factor: 4.064

7.  Neural stem cell migration toward gliomas in vitro.

Authors:  Oliver Heese; Andreas Disko; Dorothea Zirkel; Manfred Westphal; Katrin Lamszus
Journal:  Neuro Oncol       Date:  2005-10       Impact factor: 12.300

8.  Targeting breast to brain metastatic tumours with death receptor ligand expressing therapeutic stem cells.

Authors:  Tugba Bagci-Onder; Wanlu Du; Jose-Luiz Figueiredo; Jordi Martinez-Quintanilla; Khalid Shah
Journal:  Brain       Date:  2015-04-23       Impact factor: 13.501

9.  Characterisation of RT1-E2, a multigenic family of highly conserved rat non-classical MHC class I molecules initially identified in cells from immunoprivileged sites.

Authors:  Pierre Lau; Claire Amadou; Hélène Brun; Virginie Rouillon; Fiona McLaren; Anne-France Le Rolle; Margaret Graham; Geoffrey W Butcher; Etienne Joly
Journal:  BMC Immunol       Date:  2003-07-01       Impact factor: 3.615

Review 10.  Important precautions when deriving patient-specific neural elements from pluripotent cells.

Authors:  Xuejun H Parsons; Yang D Teng; Evan Y Snyder
Journal:  Cytotherapy       Date:  2009       Impact factor: 5.414

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.